About ViAqua

ViAqua Therapeutics was established in September 2014 to address the growing need for effective, affordable health management of diseases in aquaculture. To date, ViAqua has received investments from The Trendlines Group, Nutreco, VisVires New Protein, S2G Ventures, Thai Union, and the Technion–Israel Institute of Technology, with support from the Israel Innovation Authority.

​

Achievements 

Q4 2021: Name Chris Beattie, Ph.D., as an active director

​

Q2 2021: Add S2G Ventures as financial investors and Thai Union as strategic investors

​

2021: Prove the stability of the product in industrial feed production process; developed an innovative, cost-effective, scalable production process and successfully reached pilot scale

​

2019: Prepare for high-volume manufacturing and improved product efficacy

​

Q3 2018: Sign joint development agreement with Skretting SA (Nutreco’s aquaculture division) for first product, including distribution and marketing by Skretting

Q3 2018: Receive investment from Nutreco and VisVires New Protein

​

Q1 2018: Proof-of-concept for oral delivery of first product
 

ViAqua’s co-founders have Ph.D.s in molecular biology and marine biology, respectively. The Company’s management bring a broad range of business development, technology development, management, and industrial biotech experience.  

Chris Beattie, Ph.D.

Active Director
"Champion of Innovation" 

More than 30 years' experience that combines a strong scientific understanding (PhD, fish physiology) with extensive commercial experience at AKVA Group, Merck, and Skretting North America. Based in Vancouver, Canada, Chris leads AKVA Group's North American and Australasian aquaculture technology business